A Multi-Center, Prospective, Randomized, Controlled Clinical Trial Comparing the Safety and Effectiveness of ProDisc to Spinal Fusion Surgery in the Treatment of Discogenic Pain Associated With DDD in the Lumbosacral Spine
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Spinal Diseases
- Sponsor
- Synthes USA HQ, Inc.
- Enrollment
- 852
- Primary Endpoint
- Overall Success
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
The objective of this clinical investigation is to compare the safety and effectiveness of ProDisc total disc replacement to spinal fusion surgery in the treatment of discogenic pain associated with DDD in the lumbosacral spine. There will be separate study arms for one and two level cases.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Degenerative Disc Disease (DDD) in one or two adjacent vertebral levels between L3 and S
- •Diagnosis of DDD requires: a)Back and/or leg (radicular) pain; and b)Radiographic confirmation of any 1 of the following by CT, MRI, discography, plain film, myelography and/or flexion/extension films: Instability (greater than or equal to 3mm translation or 5° angulation); Decreased disc height \>2mm; Scarring/thickening of annulus fibrosis; Herniated nucleus pulposus; or Vacuum phenomenon.
- •Age between 18 and 60 years.
- •Failed at least 6 months of conservative treatment.
- •Oswestry Low Back Pain Disability Questionnaire score of at least 20/50 (40%)(Interpreted as moderate/severe disability).
- •Psychosocially, mentally and physically able to fully comply with this protocol including adhering to follow-up schedule and requirements and filling out forms.
- •Signed informed consent.
Exclusion Criteria
- •No more than 2 vertebral levels may have DDD and all diseased levels, either one or two, must be treated.
- •Patients with involved vertebral endplates dimensionally smaller than 34.5mm in the medial-lateral and/or 27mm in the anterior-posterior directions.
- •Known allergy to titanium, polyethylene, cobalt, chromium, or molybdenum.
- •Prior fusion surgery at any vertebral level.
- •Clinically compromised vertebral bodies at the affected level(s) due to current or past trauma.
- •Radiographic confirmation of facet joint disease or degeneration.
- •Lytic spondylolisthesis or spinal stenosis.
- •Degenerative spondylolisthesis of grade \>
- •Back or leg pain of unknown etiology.
- •Osteopenia or Osteoporosis: A screening questionnaire for osteoporosis, SCORE (Simple Calculated Osteoporosis Risk Estimation), will be used to screen patients to determine if a DEXA scan is required. If DEXA is required, exclusion will be defined as a DEXA bone density measured T score less than
Outcomes
Primary Outcomes
Overall Success
Time Frame: 60 Months
Overall success was a composite endpoint. A ProDisc patient was considered an overall success if, and only if, ALL of the following criteria were met: 1. ODI score improved by at least 15% from baseline; 2. SF-36 score improved from baseline; 3. Neurologic parameters maintained or improved from baseline; 4. No re-operations required to modify or remove the implant; and 5. Independent radiographic review confirmed no migration/subsidence, radiolucency, loss of disc height, loss of range of motion, or boney fusion. A Fusion patient was a considered to be a success if, and only if, ALL of the following criteria were met: Items numbered 1-3, above; 4. No re-operations required to modify the fusion site or correct a complication with an implant; and 5. Independent radiographic review confirmed strong evidence of fusion and no motion, visible gaps in fusion mass, loss of disc height, migration/subsidence, implant loosening, halos, or radiolucencies